<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>8(4)</volume><submitter>Horiuchi Y</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Reports indicate that PDLIM5 is involved in mood disorders. The PDLIM5 (PDZ and LIM domain 5) gene has been genetically associated with mood disorders; it's expression is upregulated in the postmortem brains of patients with bipolar disorder and downregulated in the peripheral lymphocytes of patients with major depression. Acute and chronic methamphetamine (METH) administration may model mania and the evolution of mania into psychotic mania or schizophrenia-like behavioral changes, respectively.&lt;h4>Methods&lt;/h4>To address whether the downregulation of PDLIM5 protects against manic symptoms and cause susceptibility to depressive symptoms, we evaluated the effects of reduced Pdlim5 levels on acute and chronic METH-induced locomotor hyperactivity, prepulse inhibition, and fo</pubmed_abstract><journal>PloS one</journal><pagination>e59320</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC3620230</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Experimental evidence for the involvement of PDLIM5 in mood disorders in hetero knockout mice.</pubmed_title><pmcid>PMC3620230</pmcid><pubmed_authors>Ishikawa M</pubmed_authors><pubmed_authors>Horiuchi Y</pubmed_authors><pubmed_authors>Tanabe Y</pubmed_authors><pubmed_authors>Arinami T</pubmed_authors><pubmed_authors>Kaito N</pubmed_authors><pubmed_authors>Iijima Y</pubmed_authors><pubmed_authors>Ishiguro H</pubmed_authors></additional><is_claimable>false</is_claimable><name>Experimental evidence for the involvement of PDLIM5 in mood disorders in hetero knockout mice.</name><description>&lt;h4>Background&lt;/h4>Reports indicate that PDLIM5 is involved in mood disorders. The PDLIM5 (PDZ and LIM domain 5) gene has been genetically associated with mood disorders; it's expression is upregulated in the postmortem brains of patients with bipolar disorder and downregulated in the peripheral lymphocytes of patients with major depression. Acute and chronic methamphetamine (METH) administration may model mania and the evolution of mania into psychotic mania or schizophrenia-like behavioral changes, respectively.&lt;h4>Methods&lt;/h4>To address whether the downregulation of PDLIM5 protects against manic symptoms and cause susceptibility to depressive symptoms, we evaluated the effects of reduced Pdlim5 levels on acute and chronic METH-induced locomotor hyperactivity, prepulse inhibition, and fo</description><dates><release>2013-01-01T00:00:00Z</release><publication>2013</publication><modification>2026-04-07T19:42:18.232Z</modification><creation>2019-03-26T23:14:04Z</creation></dates><accession>S-EPMC3620230</accession><cross_references><pubmed>23593136</pubmed><doi>10.1371/journal.pone.0059320</doi></cross_references></HashMap>